13 July 2023
13 July 2023
The SkyePay system allows patients to receive payments for participating in clinical trials.
The investigation combines Ocrevus’ subcutaneous formulation with Halozyme’s drug delivery technology.
After releasing new efficacy data, Direct Biologics continues to investigate ExoFlo in a Phase III ARDS trial.
Verve takes a different approach for its renal denervation system, as the treatment space gains momentum in 2023.
The sensor is implanted into the body’s largest vein to help monitor total body fluid.
The US-based biopharmaceutical company has presented an IND application to FDA for its orally inhaled dry powder.
Leap plans to start enrolling patients for Part B in upcoming 12 months.
The trial is anticipated to be initiated in the second half of this year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
